There are over 5 million patients suffering from CHF in the United Stated with an additional 550,000 cases diagnosed each year. The estimated cost of CHF to the US healthcare system is estimated to be over $30 BN and continues to grow each year. CHF is a cardiac condition in which the heart fails to pump blood and reaching it from the lungs at the required rate. As a result, the lung tissue becomes congested, oxygen and CO2 diffusion is slowed such that oxygen supply to the body organs is reduced while CO2 accumulates in the tissues. The EchoSense TPD diagnostic platform delivers high performance with sensitivity and specificity above 85%. This performance was achieved for diagnosis of CHF, differential diagnosis of CHF versus COPD as well as for other conditions that result in respiratory distress.